Status:
WITHDRAWN
Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Lead Sponsor:
Al-Rasheed University College
Collaborating Sponsors:
Baghdad Medical City
Conditions:
Newly Diagnosed Multiple Myeloma
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patient...
Eligibility Criteria
Inclusion
- Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)
- Age above 18 years old
Exclusion
- Age below 18 years
- Smoldering MM
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04348006
Start Date
March 1 2020
End Date
July 30 2021
Last Update
April 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baghdad Hematology center - Baghdad Medical City
Baghdad, Bab-Almuadham, Iraq, 12221